Canaccord Genuity Initiates Coverage On LB Pharmaceuticals with Buy Rating, Announces Price Target of $65

Canaccord Genuity analyst Sumant Kulkarni has initiated coverage on LB Pharmaceuticals (NASDAQ: LBRX) with a Buy rating. The firm has set a price target of $65 for the stock.